Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
27 Jul 2022 | On business and financial situation | The Company releases the press release related to the first half 2022 financial results | Download |
04 Jul 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2022 | Download |
30 Jun 2022 | Other relevant information | The Company informs about the dividends payment | Download |
16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
Pages
Date | Title | Description | |
---|---|---|---|
27 Feb 2014 | Informe anual de remuneraciones de consejeros 2013 | Download | |
27 Nov 2013 | Acuerdos estratégicos con terceros | Download | |
26 Nov 2013 | Acuerdos estratégicos con terceros | Download | |
07 Nov 2013 | Información sobre resultados (4) | Download | |
07 Nov 2013 | Información sobre resultados (3) | Download |